论文部分内容阅读
目的评价不同剂量景天通脉方对动脉粥样硬化斑块的抑制作用。方法健康新西兰兔54只随机分为:正常对照组,高胆固醇组(模型组),血脂康组,景天通脉方小、中、大剂量组,共6组;除正常对照组外,其余大鼠采用高胆固醇饲料并免疫损伤诱发的动脉粥样硬化斑块模型,观察各组血脂和C-反应蛋白(CRP)以及主动脉斑块/内膜面积比、内/中膜厚度比等并比较。结果对血脂的影响:模型组与正常对照组比较,血清总胆固醇(TC)、甘油三酯(TG)及低密度脂蛋白胆固醇(LDL-C)均升高,差异均有统计学意义(P<0.05);血脂康组及景天通脉方小、中、大剂量组TC、LDL-C均明显低于模型组(P<0.05),景天通脉方中剂量组明显低于小、大剂量组及血脂康组(P<0.05);TG景天通脉方小、中、大剂量组及血脂康组与模型组比较差异无统计学意义(P>0.05);而高密度脂蛋白胆固醇(HDL-C)景天通脉方大剂量组、血脂康组高于景天通脉方小、中剂量组,正常对照组和模型组(P<0.05)。对CRP的影响:模型组明显高于正常对照组(P<0.05),景天通脉方3组、正常对照组、血脂康组间比较差异均无统计学意义(P>0.05)。正常对照组无斑块和内、中膜增厚,景天通脉方组与模型组比较,斑块面积、内膜厚度、中膜厚度、斑块/内膜面积比、内/中膜厚度比均明显下降(P<0.05),景天通脉方中剂量组明显低于小、大剂量组及血脂康组(P<0.05)。结论景天通脉方具有抑制动脉粥样硬化的作用,可能是通过调脂、抗炎作用来完成,效应以中剂量(人的等效剂量)为佳。
Objective To evaluate the inhibitory effect of different doses of Jingtian Tongmai on atherosclerotic plaque. METHODS: Fifty-four healthy New Zealand rabbits were randomly divided into normal control group, high cholesterol group (model group), Xuezhikang group, Jingtian Tongmai group small, medium and large dose groups, altogether 6 groups; except normal control group, the rest Rats were treated with high-cholesterol diet and immune injury-induced atherosclerotic plaque model. Blood lipids and C-reactive protein (CRP), aortic plaque/intimal area ratio, and ratio of intima/media thickness were observed in each group. Compare. The effect of the results on blood lipids: Compared with the normal control group, serum total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) were increased in the model group, and the differences were statistically significant (P<0.05). <0.05); Xuezhikang group and Jingtian Tongmai prescription small, medium and high dose group TC, LDL-C were significantly lower than the model group (P <0.05), Jing Tian Tong Mai Fang dose group was significantly lower than small, High-dose group and Xuezhikang group (P<0.05); There was no significant difference in TG between Jingtian Tongmai small, medium and large dose group and Xuezhikang group compared with model group (P>0.05); and high-density lipoprotein Cholesterol (HDL-C) in Jingtian Tongmai high-dose group and Xuezhikang group were higher than Jingtian Tongmai small and medium dose group, normal control group and model group (P<0.05). The effect on CRP was significantly higher in the model group than in the normal control group (P<0.05). There was no significant difference between the Jingtian Tongmai 3 group, the normal control group, and Xuezhikang group (P>0.05). In the normal control group, there were no plaques and thickening of the medial and medial membranes. Compared with the model group, the Jingtian Tongmai treatment group had more plaque area, intimal thickness, media thickness, plaque/intimal area ratio, and intima/media thickness. The ratio was significantly decreased (P<0.05). The Jingtian Tongmao middle dose group was significantly lower than the small, high dose group and Xuezhikang group (P<0.05). Conclusion Jingtian Tongmai prescription has the effect of inhibiting atherosclerosis, which may be achieved through lipid-regulating and anti-inflammatory effects. The effect is best at moderate dose (human equivalent dose).